Bio
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.
Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering
Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis
Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China
Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials
BIO Undergoes Transformative Restructuring for Future Growth
BIO, lobbying group, reorganization, restructuring, layoffs, future growth, transformation, biotechnology industry.
Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces
Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
Barinthus Bio’s HPV Immunotherapy Fails to Demonstrate Statistically Significant Efficacy in Early Study
Barinthus Bio, HPV immunotherapy, VTP-200, early study, underwhelming results, efficacy
Boundless Bio Joins 2024 IPO Surge Amidst Prominent Oncology Trial Outcomes
Boundless Bio, Initial Public Offering (IPO), Cancer-focused biotech, 2024 IPO rally, Oncology trials, Clinical data readouts